These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12883204)

  • 61. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
    Eapen M; Giralt SA; Horowitz MM; Klein JP; Wagner JE; Zhang MJ; Tallman MS; Marks DI; Camitta BM; Champlin RE; Ringdén O; Bredeson CN; Martino R; Gale RP; Cairo MS; Litzow MR; deLima M
    Bone Marrow Transplant; 2004 Oct; 34(8):721-7. PubMed ID: 15322568
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
    Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CD123 is a useful immunohistochemical marker to facilitate diagnosis of acute graft-versus-host disease in colon.
    Lin J; Chen S; Zhao Z; Cummings OW; Fan R
    Hum Pathol; 2013 Oct; 44(10):2075-80. PubMed ID: 23791208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Very late appearance of acute graft-versus-host disease after tapering immunosuppression.
    Wollina U; Sayer HG; Wollina K; Graefe T
    J Dermatol; 2001 Dec; 28(12):734-6. PubMed ID: 11804070
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Involvement of TNF-alpha secreting macrophages in lethal forms of human graft-versus-host disease.
    Facon T; Jouet JP; Noel-Walter MP; Bloget F; Bauters F; Janin A
    Bone Marrow Transplant; 1997 Sep; 20(6):511-5. PubMed ID: 9313887
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Elevated levels of soluble ICAM-1 in serum of patients with acute myeloid leukemia undergoing bone marrow transplantation.
    Maeda Y; Chihara J; Horiuchi F; Miyatake J; Tatsumi Y; Urase F; Irimajiri K; Nakajima S; Horiuchi A
    Am J Hematol; 1996 Jul; 52(3):227-8. PubMed ID: 8756095
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum levels of soluble syndecan-1 in Hodgkin's lymphoma.
    Vassilakopoulos TP; Kyrtsonis MC; Papadogiannis A; Nadali G; Angelopoulou MK; Tzenou T; Dimopoulou MN; Siakantaris MP; Kontopidou FN; Kalpadakis C; Kokoris SI; Dimitriadou EM; Tsaftaridis P; Pizzolo G; Pangalis GA
    Anticancer Res; 2005; 25(6C):4743-6. PubMed ID: 16334170
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Stool smears for diagnosis of intestinal acute graft-versus-host disease.
    Hirano K; Kondo F; Kondo Y; Kurosawa K; Suwabe S; Noguchi Y; Miura N; Kakuda H; Sato T; Niimi H
    Bone Marrow Transplant; 1999 Oct; 24(7):799-801. PubMed ID: 10516685
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Syndecan-1/CD138 expression in normal myeloid, acute lymphoblastic and myeloblastic leukemia cells.
    Seftalioglu A; Karakus S
    Acta Histochem; 2003; 105(3):213-21. PubMed ID: 13677614
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cultured epithelial allograft for the management of cutaneous graft-versus-host disease following stem-cell transplantation.
    Milner SM; Cordova AC; Leffell M; Price LA
    Transplantation; 2011 Nov; 92(9):e53-4. PubMed ID: 22027899
    [No Abstract]   [Full Text] [Related]  

  • 72. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
    Aref S; Goda T; El-Sherbiny M
    Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Syndecan-1 (CD138) expression in acute myeloblastic leukemia cells--an immuno electron microscopic study.
    Seftalioglu A; Karakus S; Dundar S; Can B; Erdemli E; Irmak MK; Oztas E; Korkmaz C; Yazar F; Cavusoglu I
    Acta Oncol; 2003; 42(1):71-4. PubMed ID: 12665334
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease.
    Reinhardt K; Foell D; Vogl T; Mezger M; Wittkowski H; Fend F; Federmann B; Gille C; Feuchtinger T; Lang P; Handgretinger R; Andreas Bethge W; Holzer U
    J Immunol; 2014 Oct; 193(7):3355-65. PubMed ID: 25187661
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy.
    Anttonen A; Leppä S; Ruotsalainen T; Alfthan H; Mattson K; Joensuu H
    Lung Cancer; 2003 Aug; 41(2):171-7. PubMed ID: 12871780
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Blood bioamines, cortisol and aminoacid levels in leukemic patients.
    Singh JN; Chansouria JP; Singh VP; Udupa KN
    Indian J Cancer; 1989 Dec; 26(4):222-6. PubMed ID: 2636208
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations.
    Anttonen A; Leppä S; Heikkilä P; Grenman R; Joensuu H
    J Cancer Res Clin Oncol; 2006 Jul; 132(7):451-7. PubMed ID: 16557382
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
    Dhodapkar MV; Kelly T; Theus A; Athota AB; Barlogie B; Sanderson RD
    Br J Haematol; 1997 Nov; 99(2):368-71. PubMed ID: 9375756
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
    Seidel C; Sundan A; Hjorth M; Turesson I; Dahl IM; Abildgaard N; Waage A; Borset M
    Blood; 2000 Jan; 95(2):388-92. PubMed ID: 10627439
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Could mucin 16 and colony-stimulating factor 2-receptor beta possible graft versus host disease biomarkers? Medical hypotheses.
    Souza MM; de Paula FM; Hsieh R; Macedo MC; Corral MA; Nunes TB; De Paula F; Lourenço SV
    Med Hypotheses; 2017 Mar; 100():89-93. PubMed ID: 28236856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.